The cylindrical DC magnetron discharge : I. Particle-in-cell simulationVAN DER STRAATEN, T. A; CRAMER, N. F; FALCONER, I. S et al.Journal of physics. D, Applied physics (Print). 1998, Vol 31, Num 2, pp 177-190, issn 0022-3727Article

The cylindrical DC magnetron discharge : II. The negative space charge modeVAN DER STRAATEN, T. A; CRAMER, N. F; FALCONER, I. S et al.Journal of physics. D, Applied physics (Print). 1998, Vol 31, Num 2, pp 191-206, issn 0022-3727Article

Explaining variability in ciclosporin exposure in adult kidney transplant recipientsPRESS, Rogier R; PLOEGER, Bart A; DEN HARTIGH, Jan et al.European journal of clinical pharmacology. 2010, Vol 66, Num 6, pp 579-590, issn 0031-6970, 12 p.Article

Pharmacogenetics in the Cancer Clinic: From Candidate Gene Studies to Next-Generation SequencingGUCHELAAR, H.-J; GELDERBLOM, H; VAN DER STRAATEN, T et al.Clinical pharmacology and therapeutics. 2014, Vol 95, Num 4, pp 383-385, issn 0009-9236, 3 p.Article

GSTP I Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan : a study of the Dutch Colorectal Cancer GroupKWEEKEL, D. M; KOOPMAN, M; ANTONINI, N. F et al.British journal of cancer. 2008, Vol 99, Num 8, pp 1316-1321, issn 0007-0920, 6 p.Article

Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancerPANDER, J; WESSELS, J. A. M; GELDERBLOM, H et al.Annals of oncology. 2011, Vol 22, Num 5, pp 1147-1153, issn 0923-7534, 7 p.Article

UGTIAI*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer : a Dutch Colorectal Cancer Group studyKWEEKEL, D. M; GELDERBLOM, H; VAN DER STRAATEN, T et al.British journal of cancer. 2008, Vol 99, Num 2, pp 275-282, issn 0007-0920, 8 p.Article

CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trialDEZENTJE, V. O; VAN SCHAIK, R. H. N; NORTIER, J. W. R et al.Breast cancer research and treatment. 2013, Vol 140, Num 2, pp 363-373, issn 0167-6806, 11 p.Article

Feasibility of pharmacy-initiated pharmacogenetic screening for CYP2D6 and CYP2C19SWEN, J. J; VAN DER STRAATEN, T; WESSELS, J. A. M et al.European journal of clinical pharmacology. 2012, Vol 68, Num 4, pp 363-370, issn 0031-6970, 8 p.Article

The Exon-3 Deleted Growth Hormone Receptor Polymorphism Predisposes to Long-Term Complications of AcromegalyWASSENAAR, M. J. E; BIERMASZ, N. R; KLOPPENBURG, M et al.The Journal of clinical endocrinology and metabolism. 2009, Vol 94, Num 12, pp 4671-4678, issn 0021-972X, 8 p.Article